Prime Medicine PRME Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | $4.63M+55.3% | $5.98M+647% | $4.96M+739% | $3.85M+551% | ||
| $154.18M-2.5% | $160.64M+3.4% | $160.03M-1.6% | $156.38M-4.2% | $158.08M+2.1% | ||
| $56.47M+8.0% | $52.35M+4.4% | $49.91M-2.0% | $52.8M+11.6% | $52.29M+15.2% | ||
| $210.65M+0.1% | $212.98M+3.7% | $209.94M-7.6% | $209.18M-6.7% | $210.36M-1.6% | ||
| -$206.61M0.0% | -$208.35M-2.9% | -$203.96M+9.9% | -$204.22M+8.6% | -$206.52M+3.1% | ||
| $8.24M+88.4% | $7.21M+9.5% | $6.63M-5.9% | $4.95M-17.1% | $4.37M-49.5% | ||
| -$198.37M+1.8% | -$201.14M-2.7% | -$197.34M+10.0% | -$199.28M+8.4% | -$202.01M+1.2% | ||
| -$1.25+22.4% | -$1.37+17.0% | -$1.44+30.1% | -$1.56+28.1% | -$1.61+26.1% | ||
| -$199.14M+0.4% | -$201.03M-2.4% | -$196.8M+10.8% | -$197.38M+9.5% | -$200.01M+3.9% | ||
| -$206.61M0.0% | -$208.35M-2.9% | -$203.96M+9.9% | -$204.22M+8.6% | -$206.52M+3.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Prime Medicine's revenue?
- Prime Medicine (PRME) generated $4.6M in revenue over the trailing twelve months, up 55.3% year over year.
- Is Prime Medicine profitable?
- Prime Medicine is not currently profitable: it reported a net loss of $198.4M over the trailing twelve months, a -4342.4% net margin.
- What is Prime Medicine's earnings per share?
- Prime Medicine's diluted EPS over the trailing twelve months is $-1.25.
- Where does Prime Medicine's income statement data come from?
- Every line is extracted from Prime Medicine's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
